Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. specializes in the development and production of traditional Chinese medicine and biopharmaceuticals, primarily focusing on the treatment of chronic diseases. The company operates primarily in China, leveraging its strong R&D capabilities and extensive distribution network to maintain a competitive edge in the rapidly evolving biotechnology sector.
Zhejiang Shouxiangu generates revenue through the sale of its proprietary pharmaceutical products, which are often priced at a premium due to their unique formulations and efficacy. The company benefits from a strong brand reputation and a loyal customer base, allowing for pricing power in a competitive market.
Regulatory approvals for new drug formulations
Market demand for traditional Chinese medicine
Partnerships with healthcare providers
Changes in healthcare policies affecting reimbursement rates
Regulatory changes impacting the approval process for new drugs
Technological disruption in the biotechnology sector
Emergence of new competitors in the traditional Chinese medicine space
Potential for large pharmaceutical companies to enter the market
Negative net income growth impacting investor confidence
High capital expenditures affecting cash flow
moderate - The company's performance is somewhat linked to GDP growth and consumer spending, particularly in the healthcare sector, which can be sensitive to economic downturns.
Interest rates affect the company's cost of capital for R&D and expansion projects. Higher rates could lead to increased financing costs, potentially impacting profitability and valuation multiples.
minimal - The company has a low debt-to-equity ratio of 0.25, indicating limited reliance on external financing.
growth - Investors looking for potential high returns from innovative healthcare solutions may find this company appealing.
high - The stock has shown significant volatility, with a 1-year return of -29.7%, indicating potential for large price swings.
